CN105233108A - Pharmaceutical composition for treating brain gliomas and application of pharmaceutical composition - Google Patents
Pharmaceutical composition for treating brain gliomas and application of pharmaceutical composition Download PDFInfo
- Publication number
- CN105233108A CN105233108A CN201510627458.4A CN201510627458A CN105233108A CN 105233108 A CN105233108 A CN 105233108A CN 201510627458 A CN201510627458 A CN 201510627458A CN 105233108 A CN105233108 A CN 105233108A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- ait
- traditional chinese
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating brain gliomas and application of the pharmaceutical composition. The pharmaceutical composition is prepared from filtrate obtained by subjecting traditional Chinese medicinal materials to heat reflux extraction by an ethanol solution. The pharmaceutical composition comprises, by weight, 15-25 parts of sargassum pallidum (Turn.) C.Ag., 30-37 parts of vernonia patula (Ait.) Merr., 30-37 parts of cynodon dactylon (L.) Pers., 10-18 parts of airpotato yam rhizome, 9-15 parts of fiveleaf akebia fruit, 9-15 parts of flowers of fragrant plantainlily, 11-20 parts of common burreed rhizome, 9-15 parts of concretio silicea bambusae and 9-15 parts of gastrodia tuber. The pharmaceutical composition gives play to efficacy by inducing glioma cell apoptosis by multiple target points, thereby having good brain glioma treatment activity.
Description
Technical field
The invention belongs to technical field of Chinese medicine, in particular to a kind of pharmaceutical composition and application thereof for the treatment of cerebral glioma.
Background technology
Cerebral glioma is that one of tumor the most common on mankind occurs, and its deterioration degree is very high.General from making a definite diagnosis, the life-span of patient is no more than 1 year.As one of tumor the most common in central system disorder, cerebral glioma accounts for the 30%-50% of adult's intracranial tumor, has the feature such as easy recurrence, treatment difficulty.Still adopt operation to be main to the treatment means of cerebral glioma at present, radiotherapy chemotherapy is auxiliary.Due to the invasive growth of cerebral glioma, can not excise completely during operation, thus also just to determine chemotherapy be an of paramount importance ring in auxiliary treatment after human glioma operation, but cerebral glioma is to the drug resistance of many chemotherapeutics, cause the therapeutic effect of the clinical chemotherapy of cerebral glioma all undesirable.Therefore, find to cerebral glioma more effectively and the Chinese herbal and crude drugs preparations of anti-drug resistance, and to inquire into its mechanism be one of problem instantly in the urgent need to address.
Summary of the invention
In view of the deficiency that surgical operation and chemotherapy exist, the object of this invention is to provide a kind of Chinese medicine composition and application thereof for the treatment of cerebral glioma.
In order to realize the object of instinct invention, inventor carries out research and persistent exploration by lot of experiments to Chinese medicine material, finally obtains following technical scheme:
A kind of pharmaceutical composition for the treatment of cerebral glioma, this pharmaceutical composition is obtained by the filtrate of traditional Chinese medicinal material raw materials through alcoholic solution circumfluence distillation, by weight, described traditional Chinese medicinal material raw materials comprises: Sargassum 15-25 part, Calotropis gigantea(L.) Dry. ex Ait. f. var. procera (Ait.) 30-37 part, Herba cynodontis 30-37 part, Rhizoma Dioscoreae Bulbiferae 10-18 part, Fructus Akebiae 9-15 part, Flos Hostae Plantagineae 9-15 part, Rhizoma Sparganii 11-20 part, Concretio Silicea Bambusae 9-15 part, Rhizoma Gastrodiae 9-15 part.
Preferably, the pharmaceutical composition for the treatment of cerebral glioma described above, by weight, described traditional Chinese medicinal material raw materials is made up of Sargassum 19-22 part, Calotropis gigantea(L.) Dry. ex Ait. f. var. procera (Ait.) 32-34 part, Herba cynodontis 32-34 part, Rhizoma Dioscoreae Bulbiferae 13-15 part, Fructus Akebiae 11-13 part, Flos Hostae Plantagineae 11-13 part, Rhizoma Sparganii 14-16 part, Concretio Silicea Bambusae 11-13 part and Rhizoma Gastrodiae 11-13 part.
In a most preferred embodiment of the present invention, the pharmaceutical composition for the treatment of cerebral glioma described above, by weight, described traditional Chinese medicinal material raw materials is made up of Sargassum 20 parts, Calotropis gigantea(L.) Dry. ex Ait. f. var. procera (Ait.) 33 parts, Herba cynodontis 33 parts, Rhizoma Dioscoreae Bulbiferae 14 parts, Fructus Akebiae 12 parts, Flos Hostae Plantagineae 12 parts, Rhizoma Sparganii 15 parts, Concretio Silicea Bambusae 12 parts and 12 parts, Rhizoma Gastrodiae.
Further preferably, the as mentioned above pharmaceutical composition for the treatment of cerebral glioma, the volume fraction of the alcoholic solution that circumfluence distillation adopts is 70%-80%, more more preferably 75%.
It should be noted that, the traditional Chinese medicinal material raw materials that pharmaceutical composition of the present invention adopts has following source: Sargassum selects the dry frond of Sargassaceae plant Sargassum Sargassumpallidum (Turn.) C.Ag..Calotropis gigantea(L.) Dry. ex Ait. f. var. procera (Ait.) selects the dry herb of ironweed plant Herba Vernoniae Patulae Vernoniapatula (Ait.) Merr..Herba cynodontis selects the dry herb of grass family Cynodon plant Bermuda grass Cynodondactylon (L.) Pers..Rhizoma Dioscoreae Bulbiferae selects the dry tuber of Dioscoreaceae yam Dioscorea bulbifera L. DioscoreabulbiferaL..Fructus Akebiae selects the dry mature fruit of plants of Lardizabalaceae Caulis Akebiae Akebiaquinata (Thunb.) Decne.Flos Hostae Plantagineae selects the dried floral of liliaceous plant Flos Hostae Plantagineae Hostaplantaginea (Lam.) Ascherson..Rhizoma Sparganii selects the dry tuber of Sparganiaceae plant rhizoma scirpi SparganiumstoloniferumBuch.-Ham..Concretio Silicea Bambusae selects the dried block of juice in grass Chinese textile bamboo BambusatextilisMcClure bar.Rhizoma Gastrodiae selects the dry tuber of orchid Rhizoma Gastrodiae GastrodiaelataBlume..
Compared with prior art, pharmaceutical composition of the present invention plays drug effect by Mutiple Targets induction gum apoptosis of tumor, has the activity of better treatment cerebral glioma.In addition, the present invention is pure Chinese medicinal preparation, and to human body particularly to liver avirulence, and medicine of the present invention preparation is simple, and raw material is easy to get, and is suitable for popular use, has good potential applicability in clinical practice.
Detailed description of the invention
Be below preparation embodiment and the test of pesticide effectiveness example of Chinese medicine extract of the present invention, the present invention will be further described.But protection scope of the present invention is not limited to following examples, every technology realized based on foregoing of the present invention all belongs to scope of the present invention.
Embodiment 1: the preparation of Chinese medicine extract
Take Sargassum 2.0kg, Calotropis gigantea(L.) Dry. ex Ait. f. var. procera (Ait.) 3.3kg, Herba cynodontis 3.3kg, Rhizoma Dioscoreae Bulbiferae 1.4kg, Fructus Akebiae 1.2kg, Flos Hostae Plantagineae 1.2kg, Rhizoma Sparganii 1.5kg, Concretio Silicea Bambusae 1.2kg and Rhizoma Gastrodiae 1.2kg, merge, pulverize, be placed in traditional Chinese medicine extraction device, with the alcoholic solution circumfluence distillation three times that volumetric concentration is 75%, the alcoholic solution that first time adds medical material total amount 12 times, extracts 2h; Second time adds the alcoholic solution of medical material total amount 11 times, extracts 1.5h; The alcoholic solution that third time adds medical material total amount 10 times, extracts 1.5h; Four layers of filtered through gauze, merging filtrate, concentrating under reduced pressure to thick paste after reclaiming ethanol, lyophilization, is ground into fine powder, crosses 100 mesh sieves, obtains Chinese medicine extract, for the in vitro tests of embodiment 3.
Embodiment 2: the cultivation of Rat C 6 Glioma Cells
Rat C 6 Glioma Cells is recovered, adds RPMI-1640 culture medium containing 10% inactivated fetal bovine serum (containing NaHCO
32g/L, penicillin 100U/mL, streptomycin 100U/mL) in, culture bottle is put into containing 5%CO
2, cultivate in constant-temperature enclosed cell culture incubator under 37 DEG C of conditions, get l0 μ L exponential phase C6 cell, count with under red blood cell count(RBC) plate light microscopic, regulate concentration to make every 10 μ L containing 1 × 10
6individual cell, then adds the isotonic saline solution of 0.4% trypan blue by 1:9, confirms C6 glioma cell survival rate > 95% in 1min.
Embodiment 3: Chinese medicine extract is to the effectiveness study of cerebral glioma
Healthy SD rat, 7 week age, male, adaptability is raised after one week for test.First copy glioma model after on-test, method is as follows: adopt 10% chloral hydrate to carry out intraperitoneal injection of anesthesia, rat brain stereotactic apparatus headstock fixing head, and two ear acupunctures go deep into external auditory meatus, cut off head hair, sterilization, paving hole towel.Cut off scalp, be successively exposed to skull, determine bregma position.1mm before fontanel mid point, on the right side of sagittal suture, 3.0 ~ 3.5mm is opened on side, the C6 brain glioblastoma cell (embodiment 2 is cultivated) of inoculation exponential phase.Inoculation position is rat RCN, and from the vertical inserting needle of vaccination, calculate from contact dura mater, depth of needle is about 6mm, retreats 1mm, by 10 μ L cell suspension in microsyringe (containing having an appointment 1.0 × 10
6c6 cell), slowly inject, close with bone wax after pulling out pin, layer-by-layer suture scalp.Give 3d containing antibiotic drinking water prevention infection.10d after inoculation, row strengthening head mri, has determined whether that tumor is formed.Mice with tumor is divided at random following three groups: model control group, extract high and low dose group, often organizes 10 rats.Extract high and low dose group respectively gavage give 800, the Chinese medicine extract (prepared by embodiment 1, be mixed with medicinal liquid with purified water) of 400mg/kg, the isometric purified water of model control group gavage.Three groups of equal morning and evening each gavages every days once corresponding tested material, the time is 1 month.After giving end, often organize the inspection of rats underwent head B-sonography, record gross tumor volume, then sacrificed by decapitation rat, excised tumor tissue, 4% paraformaldehyde is fixed, and measures the tumor line of apsides, respectively organizes tumour inhibiting rate according to formulae discovery.Tumour inhibiting rate=(model control group gross tumor volume-treatment group tumors volume)/model control group gross tumor volume × 100%.It should be noted that, tumour inhibiting rate >=30% is that tumor is to medicaments insensitive; Gross tumor volume=a × b × π/6 (a is the tumor minor axis measured, and b is tumor major diameter).In addition, get tumor tissues 10% formaldehyde and fix, conventional embedding wax block.Section carries out HE dyeing, light Microscopic observation tumor cell quantity, density and downright bad situation.Result of the test is as follows:
Can be found out by the test statistics result of table 1, compared with model control group, the gross tumor volume of each dosage group of extract all significantly reduces (P < 0.05 or P < 0.01), and this illustrates that pharmaceutical composition of the present invention has the effect suppressing cerebral glioma growth.
Table 1 respectively group rats with brain glioma gross tumor volume and tumour inhibiting rate compares
Compare with model control group,
★p < 0.05,
★ ★p < 0.01.
Can be found out by the pathological section after observing HE dyeing, the tumor cell that in model control group C6 glioma, visible growth is active, dense clusters, oncocyte atypia is obvious, and the large engrain of nucleus, karyokinesis is as common.Extract low dose group tumor cell quantity comparatively matched group reduces, and converges together in garland shape around hypertrophy thin vessels or necrosis region.Extract high dose group C6 growth of glioma cells density comparatively model control group reduces more obvious, and cell volume diminishes, and karyomorphism is relatively regular, has large stretch of downright bad, and visible karyopyknotic apoptotic cell.
Claims (5)
1. treat the pharmaceutical composition of cerebral glioma for one kind, it is characterized in that: this pharmaceutical composition is obtained by the filtrate of traditional Chinese medicinal material raw materials through alcoholic solution circumfluence distillation, by weight, described traditional Chinese medicinal material raw materials comprises: Sargassum 15-25 part, Calotropis gigantea(L.) Dry. ex Ait. f. var. procera (Ait.) 30-37 part, Herba cynodontis 30-37 part, Rhizoma Dioscoreae Bulbiferae 10-18 part, Fructus Akebiae 9-15 part, Flos Hostae Plantagineae 9-15 part, Rhizoma Sparganii 11-20 part, Concretio Silicea Bambusae 9-15 part, Rhizoma Gastrodiae 9-15 part.
2. treat the pharmaceutical composition of cerebral glioma according to claim 1, it is characterized in that: by weight, described traditional Chinese medicinal material raw materials is made up of Sargassum 19-22 part, Calotropis gigantea(L.) Dry. ex Ait. f. var. procera (Ait.) 32-34 part, Herba cynodontis 32-34 part, Rhizoma Dioscoreae Bulbiferae 13-15 part, Fructus Akebiae 11-13 part, Flos Hostae Plantagineae 11-13 part, Rhizoma Sparganii 14-16 part, Concretio Silicea Bambusae 11-13 part and Rhizoma Gastrodiae 11-13 part.
3. treat the pharmaceutical composition of cerebral glioma according to claim 2, it is characterized in that: by weight, described traditional Chinese medicinal material raw materials is made up of Sargassum 20 parts, Calotropis gigantea(L.) Dry. ex Ait. f. var. procera (Ait.) 33 parts, Herba cynodontis 33 parts, Rhizoma Dioscoreae Bulbiferae 14 parts, Fructus Akebiae 12 parts, Flos Hostae Plantagineae 12 parts, Rhizoma Sparganii 15 parts, Concretio Silicea Bambusae 12 parts and 12 parts, Rhizoma Gastrodiae.
4. according to claim 1 or 2 or 3, treat the pharmaceutical composition of cerebral glioma, it is characterized in that: the volume fraction of described alcoholic solution is 70%-80%.
5. claim 1 or the traditional Chinese medicinal material raw materials compositions described in 2 or 3 suppress the application in the medicine of brain glioblastoma cell propagation in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510627458.4A CN105233108A (en) | 2015-09-28 | 2015-09-28 | Pharmaceutical composition for treating brain gliomas and application of pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510627458.4A CN105233108A (en) | 2015-09-28 | 2015-09-28 | Pharmaceutical composition for treating brain gliomas and application of pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105233108A true CN105233108A (en) | 2016-01-13 |
Family
ID=55031101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510627458.4A Pending CN105233108A (en) | 2015-09-28 | 2015-09-28 | Pharmaceutical composition for treating brain gliomas and application of pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105233108A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103877237A (en) * | 2012-12-22 | 2014-06-25 | 宁波立华制药有限公司 | Application of eight-treasure particle in preparation of drugs used for treating brain glioma |
| KR20140144855A (en) * | 2013-06-12 | 2014-12-22 | 다이아텍코리아 주식회사 | A novel Chlorin e6 tromethamine salt, synthesis method of the same, and use of the same |
-
2015
- 2015-09-28 CN CN201510627458.4A patent/CN105233108A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103877237A (en) * | 2012-12-22 | 2014-06-25 | 宁波立华制药有限公司 | Application of eight-treasure particle in preparation of drugs used for treating brain glioma |
| KR20140144855A (en) * | 2013-06-12 | 2014-12-22 | 다이아텍코리아 주식회사 | A novel Chlorin e6 tromethamine salt, synthesis method of the same, and use of the same |
Non-Patent Citations (3)
| Title |
|---|
| 国家中医药管理局: "《中医中药科技成果获奖项目汇编》", 31 March 2003, 中医古籍出版社 * |
| 潘敏求等: "《中华肿瘤治疗大成》", 31 January 1996, 河北科学技术出版社 * |
| 郭二坤等: "槲皮素对大鼠脑胶质瘤抑瘤作用的体内实验研究", 《中国神经精神疾病杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103463495B (en) | Drug for treating senile postoperative acute mental disorders | |
| CN108567820B (en) | A Chinese medicinal composition for treating tumor, and its preparation method | |
| CN105998019A (en) | Medicine composition for treating brain glioma and application thereof | |
| CN115120689A (en) | Application of Xinli rehabilitation formula preparation in preparation of medicines | |
| CN103181958A (en) | Chinese herbal medicine perfusate for treating endometritis of cow and preparation method thereof | |
| CN103285230B (en) | Pharmaceutical composition for treating pharyngitis and preparation method thereof | |
| CN104474219A (en) | Drug for treating trionyx sinensis saprolegniasis caused by fungi | |
| CN109602818B (en) | Application of Chinese medicinal composition in preparation of medicine for treating mastitis, hyperplasia, mammary gland pain, swelling, and lump | |
| CN105233108A (en) | Pharmaceutical composition for treating brain gliomas and application of pharmaceutical composition | |
| CN108452240B (en) | Anti-tumor traditional Chinese medicine composition and application thereof | |
| CN103877237A (en) | Application of eight-treasure particle in preparation of drugs used for treating brain glioma | |
| CN101152173A (en) | Use of liquiritigenin in preparing medicament for treating neurodegenerative diseases | |
| CN113288937B (en) | Anti-inflammatory traditional Chinese medicine compound and preparation method and application thereof | |
| KR20140119934A (en) | Composition for improving ischemic stroke containing thistle extract | |
| CN105412898A (en) | Application of traditional Chinese medicine composition in preparing acute nephritis | |
| CN101439131B (en) | Chinese medicinal composition for treating phonosensitive nerve deafness and use thereof | |
| CN101849996A (en) | Three-drug adder-wort powder and preparation method thereof | |
| CN116270787B (en) | Application of Chinese and western compound medicine in preparation of leukemia treatment medicine | |
| CN109331031A (en) | A kind of new application of chonglou saponin VII | |
| CN103191268B (en) | Traditional Chinese medicinal composition for treating lung cancer | |
| CN117462620B (en) | Traditional Chinese medicine formula for treating lung cancer and preparation method and application thereof | |
| CN103127093A (en) | Application of arctigenin in preparation of medicine for curing or preventing brain glioma | |
| CN107296896B (en) | Pharmaceutical composition for treating glioma and preparation method thereof | |
| KR101359760B1 (en) | The pharmaceutical composition comprising the extract of Astilbe chinesis for preventing and treating the degenerative brain disease | |
| KR101788127B1 (en) | Composition of the extract of combined herbs for preventing and treating hearing impairment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160113 |
|
| RJ01 | Rejection of invention patent application after publication |